Arrivo BioVentures, which emerged from stealth mode less than two years ago with $49 million in funding and four drug candidates, has raised another $45 million and plans to advance its treatment focused on major depression disorder or MDD.
Igor Jablokov is Pryon's founder and CEO. He published the following letter Tuesday explaining in his view what a new cash in fusion of $100 million means for his company - and artificial intelligence.